EGFR and non-small cell lung carcinoma: The advent of the third-generation TKI Osimertinib, which is an additional irreversible EGFR inhibitor of both all sensitizing mutations and the TKI resistance mutation T790M, was the most recent step in the targeted therapy of NSCLC.